Alligator Bioscience 以 350 万欧元的价格向 Orion 出售两种抗体的专利权使用费。 Alligator Bioscience sells royalty rights to Orion for two antibodies in a €3.5 million deal.
Alligator Bioscience 和 Orion Corporation 修订了他们的协议，将两种临床前双特异性抗体的专利费许可转换为全额支付的免专利费许可。 Alligator Bioscience and Orion Corporation have amended their agreement, converting a royalty-bearing license to a fully paid, royalty-free license for two preclinical bispecific antibodies. Orion 将继续开发抗体，而无需支付未来的里程碑或特许权使用费，向 Alligator 一次性支付 350 万欧元。 Orion will continue developing the antibodies without paying future milestones or royalties, making a one-time payment of €3.5 million to Alligator. 这项协议使鳄鱼公司能够集中精力推动其主要候选人Mitazalimab向第三阶段发展迈进。 This deal allows Alligator to focus on advancing its lead candidate, mitazalimab, towards Phase 3 development.